Frontlight ResearchEarly access
CompletedNo phase
The Pilot Study of Medical Device-Neuclare for Patients With Idiopathic Normal Pressure Hydrocephalus (iNPH)
Key facts
- Who runs it
- Deepsonbio
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 20 people enrolled
- Started
- 22 Jul 2024
- Ended
- 21 Nov 2025
- Type of study
- Interventional
- Treatments tested
- Neuclare
- Record updated
- 24 August 2026
Who can take part
- Age
- 60 years to 90 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (22)Hide the full registry criteria
Who can take part
- Adults aged 60 to 90, regardless of gender
- Individuals exhibiting gait disturbances along with at least one of the following symptoms: cognitive impairment or urinary incontinence
- Evans' index > 0.3)
- When the symptoms in 2) and 3) cannot be fully explained by other neurological or non-neurological diseases
- Diagnosis of INPH based on the Investigator's clinical judgement based on criteria as described in the INPH Guidelines
Who cannot take part
- Patients who have undergone shunt surgery in the past year
- Patients taking medications that affect gait, cognition, or urinary tract function and who have had a change in medication regimen within the past 3 months
- A person who is confirmed to have organic brain lesions (e.g., cerebral edema, cerebral hemorrhage, cerebral infarction, cerebrovascular malformation, brain tumor, etc.) on a brain MRI
- Patients with metabolic disorders such as thyroid dysfunction, hyperglycemia, hypoglycemia, liver or kidney dysfunction, and long-term use of drugs that will cause cognitive decline (e.g., anticholinergic drugs)
- History of psychiatric disorder other than the inclusion criteria
- A person with a severe history of cancer/tuberculosis
- A person whose bleeding is identified due to a common procedure or surgery that may affect vital signs
- A person with an allergic reaction to MRI contrast agents such as Definity or Gadovist
- Patient with behavioral and psychological symptoms of dementia (BPSD) that make cooperation in the clinical trial difficult
- Patients with severe cognitive impairment, defined as an MMSE score of 17 or below
- Patients with a history of uncontrolled thyroid, liver, or kidney dysfunction
- Patient with pathological lesions in the brain identified by MRI
- A person who has contact dermatitis or sensitive skin abnormalities
- Patients with a high fever of 40 degrees Celsius or higher based on eardrum body temperature
- A person who is unable to perform MRI tests
- Other cases where the investigator judged that it is difficult to participate in the study
- Patients who have undergone a cerebrospinal fluid drainage test within the past 1 month
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This clinical trial aims to explore the effectiveness and safety of gait improvemen of Neuclare, a science medical device, for patients with Idiopathic Normal Pressure Hydrocephalus (iNPH) Through methods such as Timed Up \& Go Test (TUG), 10m gait , iNPH grading scale), etc, gait improvement before and after using Neuclare will be evaluated.
The group in the trial
- Treatment groupTreatment being tested
The patient with Idiopathic Normal Pressure Hydrocephalus (iNPH) who will be treated with the medical device-Neuclare
Treatment: Neuclare
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Single-arm, Open-label, Non-randomized Exploratory Clinical Trial to Verify the Efficacy and Safety of Gait and Cognitive Improvement in Patients With Idiopathic Normal Pressure Hydrocephalus (iNPH) Using the Neuclare Physical Device for Medical Use
- Record updated
- 24 August 2026